3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
6
Colorectal Neoplasms
4
Brain Neoplasms
3
Radiodermatitis
2
Pancreatic Neoplasms
2
Pain, Postoperative
2
Lung Neoplasms
2
Leiomyoma
2
Head and Neck Neoplasms
2
Warts
1
Surgical Wound
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Diseases
1
Sigmoid Neoplasms
1
Severe Acute Respiratory Syndrome
1
Sarcoma
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neuroinflammatory Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Mastocytosis
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Injury
1
Locally Advanced Cervical Cancer
1
Limited Stage Small Cell Lung Cancer
1
Leukemia, Myeloid, Acute
1
Interventions
Carboplatin
47
Etoposide
46
durvalumab
28
atezolizumab
28
Cisplatin
21
Topotecan
19
pembrolizumab
15
PM 01183
15
Nivolumab
12
Specimen Handling
11
anlotinib
9
Radiotherapy
9
Paclitaxel
9
Drug Therapy
9
Temozolomide
8
Magnetic Resonance Spectroscopy
8
AMG 757
8
Radiosurgery
7
Platinum
7
Irinotecan
7
toripalimab
6
olaparib
6
Biopsy
6
Ipilimumab
5
Injections
5
Docetaxel
5
Bevacizumab
5
trilaciclib
4
tremelimumab
4
tislelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
Sodium Chloride
×
1 year
×
Clear all
NCT04624204
2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
672 enrolled